{"id":"NCT03077438","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years","officialTitle":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-17","primaryCompletion":"2017-10-10","completion":"2017-10-10","firstPosted":"2017-03-13","resultsPosted":"2020-06-09","lastUpdate":"2022-03-28"},"enrollment":1000,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningitis","Meningococcal Meningitis","Meningococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate","otherNames":["MenACYW Conjugate vaccine"]},{"type":"BIOLOGICAL","name":"Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine","otherNames":["MENVEO®"]}],"arms":[{"label":"Group 1: MenACYW Conjugate Vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: MENVEO® Vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 (MENVEO®) vaccine in children 2 to 9 years of age in the United States (US) and Puerto Rico.\n\nPrimary objective:\n\n\\- To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine compared to that observed following the administration of a single dose of MENVEO® in children aged 2 to 9 years.\n\nSecondary objectives:\n\n* To compare the serum bactericidal assay using human complement (hSBA) antibody geometric mean titers (GMTs) of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of MENVEO® in children 2 to 9 years of age.\n* To evaluate the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine and those observed following the administration of MENVEO® in children 2 to 5 years of age, and in children 6 to 9 years of age, respectively.\n* To evaluate the hSBA vaccine seroresponse to meningococcal serogroups A, C, Y, and W before and 30 days (+14 days) post-vaccination in children 2 to 5 years of age, and in children 6 to 9 years of age, respectively.\n\nObservational objective:\n\n\\- To describe the safety profile of MenACYW Conjugate vaccine and that of the licensed MENVEO®.","primaryOutcome":{"measure":"Percentage of Participants Achieving Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine","timeFrame":"Day 30 (post-vaccination)","effectByArm":[{"arm":"Group 1: MenACYW Conjugate Vaccine","deltaMin":55.4,"sd":null},{"arm":"Group 2: MENVEO® Vaccine","deltaMin":47.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":36,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["32852352"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":498},"commonTop":["Injection Site Pain","Injection Site Erythema","Myalgia","Malaise","Injection Site Swelling"]}}